Armel Zemsi

Armel Zemsi


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2024 in Therapeutic Innovation & Regulatory Science
Verified
Journal Article
Open access
PDF file
AZArmel Zemsi
Armel Zemsi
LNLorraine Jinette Guedem Nekame
Lorraine Jinette Guedem Nekame
NMNuredin Mohammed
Nuredin Mohammed
EBElizabeth Stanley Batchilly
Elizabeth Stanley Batchilly
EDEdgard Dabira
Edgard Dabira
UDUmberto D’aLessandro
Umberto D’aLessandro
A clinical trial is any research on human subjects that involves an investigational medicinal product or device. Investigational medicinal products include unlicensed drugs or drugs used outside the product license (e.g. for a new indication) (ICH-GCP). As per the internationally accepted ICH-GCP guidelines, clinical trials should be conducted strictly per the approved protocol. However, during the lifecycle of a trial, protocol deviations may occur. Under ICH efficacy guidelines, protocol deviations are divided into non-important (minor) or important (major), and the latter can jeopardise the participant’s rights, safety or the quality of data generated by the study. Existing guidelines on protocol deviation management do not detail or standardise actions to be taken for participants, investigational products, data or samples as part of a holistic management of important protocol deviations. Herein, we propose guidelines to address the current literature gap and promote the standardisation of actions to address important protocol deviations in clinical trials. The advised actions should complement the existing local institutional review board and national regulatory authority requirements.

8 April 2025 in medRxiv
Verified
Preprint
Open access
PDF file
Cheuyem Lekeumo Fabrice ZobelCheuyem Lekeumo Fabrice Zobel
Cheuyem Lekeumo Fabrice Zobel
AZArmel Zemsi
Armel Zemsi
JNJonathan Hangi Ndungo
Jonathan Hangi Ndungo
CAChabeja Achangwa
Chabeja Achangwa
DTDavy Roméo Takpando-Le-Grand
Davy Roméo Takpando-Le-Grand
SNSaralees Nadarajah
Saralees Nadarajah
Background: Mpox, caused by the Mpox virus, is a zoonotic disease historically endemic in Central and West Africa. The Democratic Republic of Congo (DRC) bears the highest burden, with evolving epidemiology and significant public health challenges. Understanding severity and mortality trends is critical for global control efforts. Methods: This systematic review and meta-analysis followed PRISMA guidelines to synthesize evidence on Mpox severity and mortality in the DRC from 1970 to 2024. We searched PubMed, ScienceDirect, Scopus, Web of Science identifying 19 eligible studies after screening 5443 records. Data on severity and death among suspected and confirmed cases were extracted. Random-effects models addressed high heterogeneity, and subgroup analyses examined temporal trends, regional differences, and healthcare settings. Meta-regression explored sources of heterogeneity, adjusting for study year, region, and setting. Results: We included a total of 19 study reports. The pooled severity rate among 3,280 confirmed cases was 39.47% (95% confidence interval [CI]: 29.11-50.86), declining from 46.34% (95% CI: 37.07-55.87) pre-2022 to 25.83% (95% CI: 11.16-49.11) in 2022-2024. Northern (43.82%; 95% CI: 37.81-50.03) and Central (63.89%; 95% CI: 57.10-70.30) regions had higher severity than Eastern regions (26.04%; 95% CI: 8.77-56.31). Case fatality rates (CFRs) were 1.70% (95% CI: 0.72-3.95) for suspected cases and 2.46% (95% CI: 0.65-8.85) for confirmed cases, with Western DRC disproportionately affected (22.03%; 95% CI: 13.25-34.34). Community settings showed higher CFRs (3.69%; 95% CI: 0.78-15.81) than hospitals (0.77%; 95% CI: 0.32-1.84), underscoring healthcare access disparities. Meta-regression confirmed study year (p = 0.044) as significant predictors of outcomes case severity heterogeneity and study year ( p = 0.016), region ( p = 0.003) and setting ( p = 0.041), with mortality declining over time but remaining elevated in resource-limited areas. Conclusion: Mpox continues to impose a substantial burden in the DRC, with high severity and mortality rates, particularly in Western/Central regions and community settings. The observed temporal decline in severity and CFRs suggests the impact of strengthened surveillance and healthcare capacity. However, regional disparities persist might be due to inequitable healthcare access and potential differences in viral clades. Targeted interventions, including vaccination in high-risk areas, community education, and healthcare system strengthening are urgently needed.

1 January 2021 in Pan African Medical Journal
Verified
Journal Article
Open access
Boris Kevin TchoungaBoris Kevin Tchounga
Boris Kevin Tchounga
RARogers Ajeh
Rogers Ajeh
TDTatiana KATCHO DJIKEUSSI
Tatiana KATCHO DJIKEUSSI
PEPeter Ebasone
Peter Ebasone
PTPatrice Tchendjou
Patrice Tchendjou
ADAnastase Dzudie
Anastase Dzudie
Research is a vital component for the development of any country. In Cameroon, HIV Operational research is rapidly growing, however, it faces some intractable problems which can only be solved through an urgent, strategic, efficient, and collaborative approach involving key stakeholders. The Kribi meeting (09 and 10th December 2020) brought together under the auspices of the Ministry of Public Health leading HIV research organisations and connected HIV researchers and actors from different sectors. These actors disseminated and discussed recent research findings and worked out mechanisms to advance HIV research development, developed new ideas and identified priority research areas, with emphasis on translational research. The official launching and consolidation of Cam-HERO was a critical step and it is hoped that these synergistic efforts will catalyse attainment of the 95-95-95 goals in Cameroon.

1 July 2025 in Journal of Interventional Epidemiology and Public Health
Verified
Journal Article
Open access
PDF file
AZArmel Zemsi
Armel Zemsi
AHAnthony Huszar
Anthony Huszar
AFAhmed Futa
Ahmed Futa
DKDerick Kimathi
Derick Kimathi
ECEd Clarke
Ed Clarke
Introduction Lassa fever remains a significant public health threat in West Africa. Effective epidemic preparedness requires a robust clinical trial infrastructure capable of conducting GCP-compliant vaccine trials. The Advancing Research Capacity in West Africa (ARC-WA) project, funded by CEPI, aims to strengthen regional capacity for a future Phase 3 Lassa fever vaccine efficacy trial and support long-term research readiness across the region. Methods Led by a technical coordinating partnership between the International Vaccine Institute (IVI) and the Medical Research Council, The Gambia (MRCG), and supported by MMARCRO, BNITM, and a consortium management group with regional expertise, the ARC-WA project has been ongoing since January 2024 and is implemented through two tracks . Track A focuses on site-level capacity strengthening. Six clinical trial sites in Nigeria, Liberia, and Sierra Leone are receiving tailored support in infrastructure upgrades, the development of quality management systems and Standard Operating Procedures (SOPs), and comprehensive staff training in clinical operations, laboratory systems, data management, finance, and regulatory management. Track B promotes broader regional preparedness through stakeholder mapping, regional consultations, and workshops to identify gaps and define actions that enable sustainable epidemic response capabilities. Results To date, 35 sites across five countries (Nigeria, Liberia, Sierra Leone, Guinea and Benin) have been assessed for readiness. Under Track A, targeted improvements are ongoing at six sites, focusing on operational readiness for GCP-compliant trials. Track B activities have fostered national ownership and regional collaboration by engaging local stakeholders in priority-setting and planning. Conclusion The ARC-WA project is laying the groundwork for effective clinical trial implementation and long-term epidemic preparedness in West Africa. Through a dual-track approach, it addresses immediate site-level needs while advancing regional systems to support a coordinated response to future outbreaks.

17 December 2023 in BMJ Global Health
Verified
Conference Paper
Open access
PDF file
SSSheikh Omar Sillah
Sheikh Omar Sillah
AZArmel Zemsi
Armel Zemsi
BCBully Camara
Bully Camara
ASAja Nyarra Sanyang
Aja Nyarra Sanyang
DWDaisy Clara H Williams
Daisy Clara H Williams
ARAnna Roca
Anna Roca
Background The PregnAnZI-2 trial was conducted in The Gambia and in Burkina Faso to evaluate the efficacy of intrapartum azithromycin (AZI) to reduce neonatal sepsis and mortality and maternal infections. Overall, 11,983 birthing parents and their newborns (6,735 participants for Gambia Site) were recruited into the study and randomized at a 1:1 ratio to receive either AZI or placebo. The independent trial monitoring was conducted by the Clinical Trials Unit of the Medical Research Council Unit The Gambia at LSHTM and we report here the main quality measures implemented in the trial and the subsequent protocol deviations observed in The Gambia site. Methods As part of quality control measures, the trial implemented frequent retraining of trial staff on study procedures, electronic data capture systems with integrated real-time eligibility and data quality checks, and pre-prepared drug blisters numbered similarly as the randomization list and envelopes. We conducted a total of 20 monitoring visits (a site initiation visit, 18 interim monitoring visits and close out visit) and captured all the protocol deviations identified in a purposively developed database. Results Overall, there were 55 protocol deviations (PDs) identified in The Gambian site among the 6,735 women enrolled, giving a PD rate of 0,82% per participant. The most common PDs were delayed safety reporting of serious adverse events (SAEs) to ethics and sponsor (30.9% [17/55]), wrong sequence in treatment allocation (13% [7/55]) and delayed/out of window visit (7.3% [4/55]). PDs related to inappropriate consenting, and inclusion of ineligible participants represented 18% [10/55] and all other deviations 30.9% [17/55]. Conclusion With robust quality control measures, frequent onsite monitoring, and by tapping into the potential of electronic data capture systems, research teams can efficiently implement large clinical trials of high quality with very few protocol deviations in resource-limited settings.

12 February 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
AZArmel Zemsi
Armel Zemsi
ICI Cham
I Cham
MDM T Diallo
M T Diallo
EYE Youm
E Youm
ANArmanda NANGMO
Armanda NANGMO
Stephen J. AllenStephen J. Allen
Stephen J. Allen
The rapid growth of clinical trials in sub-Saharan Africa (sSA) since 2010 has increased opportunities to evaluate interventions for children. However, children with common comorbidities—malnutrition, HIV infection, and sickle cell disease (SCD)—may be systematically excluded, limiting the applicability of trial findings. We quantified the extent of such exclusions and identified trial characteristics associated with exclusion. We analysed phase 2–4 interventional trials registered between 2010 and 2023 in ClinicalTrials.gov, the International Standard Randomized Controlled Trials Number, and the Pan-African Clinical Trials Registry. Eligibility criteria were reviewed and trials classified as including, excluding, probably including, or probably excluding each condition. Exclusion proportions were calculated among trials not primarily targeting these populations. Associations between exclusion and trial characteristics (phase, period, disease area, design, and intervention type) were examined. Among 1,276 trials, primary exclusion rates were 37.0% (95% CI: 34.3–39.7) for malnutrition, 41.2% (38.4–44.1) for HIV, and 35.1% (32.5–37.9) for SCD. Exclusion varied by trial phase, intervention type, and disease area. Children with these high-risk conditions remain substantially underrepresented in paediatric trials in sSA, undermining generalisability and equity. More inclusive trial designs are needed.